drugset / Trial / NCT05675033
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.
Timeline
- Start
- 2023-01-10
- Primary completion
- 2023-01-10
- Completion
- 2024-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Serplulimab | Monoclonal antibody | 4.5 mg/kg | Intravenous |